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GASTROENTEROLOGY & HEPATOLOGY

A Case of Acute Pancreatitis Associated with
Empagliflozin
Tudor Sturzoiu MD1, Sameep Thapa, MD1, Ellen Solomon2, Suchit Bhutani, MD1
1. Department of Medicine, Thomas Jefferson University, Philadelphia, PA
2. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

ABSTRACT
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are
being prescribed increasingly more often for type 2
diabetes mellitus as well as heart failure. They have not
typically been associated with acute pancreatitis, but there
has been a steady flow of case reports implicating them
in acute pancreatitis over the years since they were initially
approved. Here, we present the case of an 82-year-old
woman with a past medical history of T2DM, COPD,
hyperlipidemia, a remote stroke, peripheral arterial disease,
and remote breast cancer now with recurrent localized
breast cancer on treatment with ademaciclib and letrozole
who presented to the emergency department with
abdominal pain, weakness, decreased oral intake, and
nausea and vomiting. These symptoms started two weeks
after the initiation of the SGLT-2 inhibitor empagliflozin for
her T2DM. Initial labs were notable for sodium of 129,
glucose of 409, a normal anion gap, beta hydroxybutyrate
of 4.6, serum creatinine of 0.92, calcium of 9.8, total
bilirubin of 3.0 with direct bilirubin 2.6, alkaline phosphatase
of 773, AST of 330, ALT of 446, lipase of 1,159, triglycerides
of 237, and leukocyte count of 4.9. Following admission,
CT and MRCP demonstrated pancreatitis with no
intrahepatic or extrahepatic ductal dilation, gallstones
choledocholithiasis, or other obvious etiology of her
presentation. Her symptoms improved with supportive
care following the discontinuation of her SGLT-2 inhibitor
and she was discharged to inpatient rehab shortly after
presentation. This case highlights the importance of
keeping the uncommon diagnosis of SGLT-2 inhibitor
associated pancreatitis in mind in patients who present
with acute pancreatitis.

INTRODUCTION
According to the Centers for Disease Control, the
prevalence of type 2 diabetes mellitus (T2DM) in 2020
was nearly 10.5%1. Given its overall burden and the range
of complications that can arise from long-term T2DM, it
makes sense that there continue to be emerging
therapies to treat it. One of the drug classes approved
within the last decade, sodium-glucose co-transporter 2
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(SGLT-2) inhibitors, function by reducing the reabsorption
of glucose at the level of the renal tubule, thus causing
lower blood glucose levels through therapeutic
glucosuria. It has been increasingly prescribed for T2DM
and was recently approved for the treatment of heart
failure with reduced ejection fraction even in the absence
of T2DM. Pancreatitis, which has been associated with
some classes of T2DM medications, is an uncommon
side effect of SGLT-2 inhibitors. Still, there have been a
few reports of SGLT-2 inhibitors induced pancreatitis
since their approval, and it is important to keep this side
effect in mind when prescribing these drugs for the first
time or when treating someone for acute pancreatitis in
the setting of recent initiation of an SGLT-2 inhibitor2-4.
Here, we present the case of an 82-year-old woman
who presented with subacute abdominal pain caused by
pancreatitis 30 days after initiation of the SGLT-2 inhibitor
empagliflozin in the setting of poorly controlled diabetes.

CASE REPORT
Our patient is an 82-year-old woman who presented to
the emergency department in January of 2021 with
almost 2 weeks of abdominal pain with radiation to her
back, weakness, and decreased oral intake. She had
also been experiencing nausea and vomiting for 3-4
days prior to admission. Her significant past medical
history included poorly controlled T2DM with recent
Hgb-A1C of 11.1%, COPD, a remote stroke, hyperlipidemia, peripheral artery disease, and two previous
episodes of breast cancer in 1994 and 2015 now with
recurrence. Her medications included metformin,
fluticasone/salmeterol, tiotropium, albuterol,
rosuvastatin, clopidogrel, lorazepam, abemaciclib and
letrozole. She was initiated on empagliflozin to optimize
the treatment of her T2DM on at the start of December
of 2020. Additionally, she was recently diagnosed with
recurrent estrogen receptor positive, progesterone
receptor positive, human epidermal growth factor
receptor-2 negative inflammatory breast cancer of the
right breast in November of 2020, at which time she
was initiated on abemaciclib and letrozole.
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On presentation, initial vital signs included a temperature
of 96.60F, pulse of 83 beats per minute, blood pressure
of 156/75 mmHg, respiratory rate of 18, and oxygen
saturation of 96% on room air. Physical examination
was significant for lethargy, dry mucous membranes,
diffuse abdominal tenderness without rebound or
guarding, and a firm right breast mass with dimpling of
the overlying skin. Initial labs were notable for a sodium
of 129, bicarbonate of 15 (baseline 18-20) with a normal
anion gap, serum creatinine of 0.92, glucose of 409,
calcium of 9.8, total bilirubin of 3.0 with direct bilirubin
2.6, alkaline phosphatase of 773, AST of 330, ALT of
446, beta hydroxybutyrate of 4.6, lactate of 1.4, lipase of
1,159, triglycerides of 237, leukocyte count of 4.9, and
hemoglobin of 11.3. CT of the abdomen and pelvis
without contrast demonstrated peripancreatic fat
stranding and edema consistent with acute
uncomplicated pancreatitis. Notably, it also showed a
normal liver, normal bile ducts without dilation, and a
normal gallbladder without gallstones. She had held
most of her medications on her own prior to
presentation due to a concern that they could be related
to her symptoms. The following day, ultrasound of the
abdomen confirmed absence of cholelithiasis and
choledocholithiasis with normal caliber intrahepatic
and extrahepatic biliary ducts including the common
bile duct as well as a normal gallbladder without stones
or edema. It also showed signs of acute pancreatitis,
though this was better imaged on the CT scan from the
prior day. Due to concern for an occult obstructive
lesion in the biliary system in the setting of persistently
high ALP, AST, ALT, and bilirubin in the setting of
malignancy, she was sent for magnetic resonance
imaging with MRCP, which demonstrated no
intrahepatic or extrahepatic biliary ductal dilatation and
again confirmed no cholelithiasis or choledocholithiasis. It also visualized a 0.7 cm intraductal papillary
mucinous neoplasm, which was slightly increased in
size since the last time it was imaged in 2012. At this
point, her symptoms had improved significantly since
her SGLT-2 inhibitor was held, but her liver function
tests (LFTs) were persistently elevated. As such, she
underwent esophagogastroduodenoscopy with
endoscopic ultrasound, which showed diffuse
thickening of common hepatic duct and common bile
duct walls without dilation or stones. In consultation
with GI, it was determined that her persistently elevated
LFTs were in the setting of acute pancreatitis, and they
were expected to trend down over the next days to
weeks. The patient continued to improve symptomatically, and her LFTs did trend down before her eventual
discharge to inpatient rehabilitation.

22 | The Medicine Forum, Volume 23 5
https://jdc.jefferson.edu/tmf/vol23/iss1/12

DISCUSSION
SGLT-2 inhibitors have been implicated in drug-induced
pancreatitis in a few case reports2-4. A recent review
aggregated case reports of SGLT2-associated
pancreatitis and found that four reports were associated
with canagliflozin, two with empagliflozin, and one
with dapagliflozin3. Since that paper was published,
another case report for empagliflozin-induced
pancreatitis has been published4. Our case report is
the fourth that we were able to find for empagliflozin.
In the previous review, the mean time interval from
initiation of the SGLT-2 inhibitor to diagnosis of
pancreatitis was 39 days, which falls in line with the
time interval observed in this case – 30 days.
Our patient presented with clinical, laboratory and
imaging findings of acute uncomplicated pancreatitis.
In the absence of any of the other classic causes of
pancreatitis (including alcoholism, gallstones,
obstructive mass lesion in the setting of malignancy,
and hypertriglyceridemia) and the recent initiation of
an SGLT-2 inhibitor, we believe drug-induced
pancreatitis to be the most likely cause of her
presentation. Letrozole and abemaceclib were also
recently initiated, but these are less likely to be causes
of pancreatitis. We were not able to find any case
reports of pancreatitis associated with these two
agents, and in fact, letrozole has been prescribed as an
alternative to tamoxifen in a number of cases where
tamoxifen was implicated in pancreatitis5-7.
The mechanism for the development of pancreatitis is
unknown with regards to this drug class, which has
only been associated with pancreatitis in a few case
reports. It is becoming more apparent that SGLT-2
inhibitors have broader in vivo actions than just SGLT-2
inhibition in renal tubular cells, and it is possible that
some of these effects are responsible for the
development of pancreatitis. The range of conditions
for which SGLT-2 inhibitors are approved is expanding,
such that they will be prescribed increasingly more
commonly over the next years, which could lend
further insight into the extent of their physiologic
actions.
This case report highlights the importance of keeping
the rather uncommon diagnosis of SGLT-2-induced
pancreatitis in mind when treating a patient with acute
pancreatitis, as timely discontinuation of the SGLT-2
inhibitor caused improvement of symptoms in all case
reports that we reviewed.

2

Sturzoiu, MD et al.: A Case of Acute Pancreatitis Associated with Empagliflozin

REFERENCES
1. Centers for Disease Control and Prevention A GA: Centers for Disease
Control and Prevention, US Dept of Health and Human Services; 2020.
National Diabetes Statistics Report 2020. Estimates of diabetes and its
burden in the United States. Published online 2020:32.
2. Zeidan BS, Boadu C, Hernandez A, Frunzi J, Adetula I. Adverse Side
Effects: Empagliflozin-Related Acute Pancreatitis Case Report. Cureus.
2020;12(12):e12325. doi:10.7759/cureus.12325
3. Sujanani SM, Elfishawi MM, Zarghamravanbaksh P, Castillo FJC, Reich
DM. Dapagliflozin-Induced Acute Pancreatitis: A Case Report and
Review of Literature. Case Rep Endocrinol. 2020;2020:6724504.
doi:10.1155/2020/6724504
4. Dziadkowiec KN, Stawinski PM, Proenza J. Empagliflozin-Associated
Pancreatitis: A Consideration for SGLT2 Inhibitors. ACG Case Rep J.
2021;8(1):e00530. doi:10.14309/crj.0000000000000530
5. Tey TT, Maung AC, Lim KW, Hsiang JC. Acute Pancreatitis Caused
by Tamoxifen-Induced Severe Hypertriglyceridemia After 4 Years
of Tamoxifen Use. ACG Case Rep J. 2019;6(2):1-3. doi:10.14309/
crj.0000000000000025
6. Jang YH, Kim HJ. Hypertriglyceridemia-induced Severe Necrotizing
Pancreatitis Following Low Dose Tamoxifen Administration. Korean J
Pancreas Biliary Tract. 2019;24(3):111-115. doi:10.15279/kpba.2019.24.3.111
7. Kataria PSC, Kendre PP, Patel AA, Bohra MZ, Tahiliani N. Tamoxifen
Induced Pancreatitis: An Unusual Complication of Commonly
used Drug. J Clin Diagn Res. 2017;11(8):XD05-XD06. doi:10.7860/
JCDR/2017/27440.10467

Published by Jefferson Digital Commons, 2022

The Medicine Forum, Volume 23 | 23 5

3

The Medicine Forum, Vol. 23 [2022], Art. 12

"Not fragile like a flower, fragile like a bomb" – Heping Sheng, MD
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